Collectively, these data suggest that SLX1 expression serves as a predictive biomarker of PARP inhibitor responsiveness and that targeting SLX1 represents an effective strategy to enhance the efficacy of PARP inhibitors in breast cancer. The gene discussed is PARP1; the disease is breast cancer.